News & Updates
Showing Cardiology articles
Showing

Survodutide reduces body weight, improves cardiometabolic parameters in people with obesity & T2D
Survodutide, a glucagon receptor–glucagon-like peptide-1 (GLP-1) receptor dual agonist, provides sustained weight loss and improves glycaemic control and other cardiometabolic parameters in individuals with obesity and type 2 diabetes (T2D), primary results of the phase III SYNCHRONIZE-2 trial have shown.

Survodutide preferentially reduces metabolically harmful fat in obesity
Survodutide preferentially reduces metabolically harmful fat while largely preserving lean mass and muscle mass, according to new data from a body composition substudy of the phase III SYNCHRONIZE-1 trial involving adults with obesity without diabetes.

Parathyroidectomy reduces MACE risk in primary hyperparathyroidism
In patients with primary hyperparathyroidism (PHPT), parathyroidectomy significantly reduces the risk of major adverse cardiovascular events (MACE), a population-wide target trial emulation (TTE) study in Hong Kong has shown.





